Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Petty, W J ^a,b   Aklilu, Mebea ^a,b   Varela, Victor A ^a,b   Lovato, James ^a,b   Savage, Paul D ^a,b   Miller, Antonius A ^a,b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin (1 7); Placental growth factor; Sarcoma

Indexed keywords

ANGIOGENIC FACTOR; ANGIOTENSIN[1-7]; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACENTAL GROWTH FACTOR; TUMOR MARKER; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SENSITIVITY; ENDOTHELIOMA CELL LINE; ENZYME REPRESSION; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE REPRESSION; GENETIC ASSOCIATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RNA TRANSLATION; SARCOMA; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION PROCESS; VASCULAR SARCOMA;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN I; ANIMALS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MIDDLE AGED; NEOPLASMS, VASCULAR TISSUE; PEPTIDE FRAGMENTS; PREGNANCY PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84866002486     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-404     Document Type: Article

References (25)

1. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010, 10:745-759. 10.1038/nrc2945, 20966920.
2. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999, 34:950-957. 10.1161/01.HYP.34.4.950, 10523390.
3. Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angiogenesis. Life Sci 2000, 66:67-76.
4. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003, 42:574-579. 10.1161/01.HYP.0000090322.55782.30, 12953014.
5. Anton L, Merrill DC, Neves LA, Brosnihan KB. Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor. Endocrine 2007, 32:212-218. 10.1007/s12020-007-9022-1, 18008188.
6. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996, 28:104-108. 10.1161/01.HYP.28.1.104, 8675248.
7. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009, 8:1676-1683. 10.1158/1535-7163.MCT-09-0161, 3314264, 19509262.
8. Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res 2009, 69:s103.
9. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 2009, 15:7398-7404. 10.1158/1078-0432.CCR-09-1957, 19920106.
10. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011, 117:4939-4947. 10.1002/cncr.26098, 3135685, 21480200.
11. Gordillo G, Fang H, Khanna S, Harper J, Phillips G, Sen CK. Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm. Antioxid Redox Signal 2009, 11:47-58. 10.1089/ars.2008.2150, 2933151, 18817478.
12. Zhu Y, Cuevas IC, Gabriel RA, Su H, Nishimura S, Gao P, Fields A, Hao Q, Young WL, Yang GY, Boudreau NJ. Restoring transcription factor HoxA5 expression inhibits the growth of experimental hemangiomas in the brain. J Neuropathol Exp Neurol 2009, 68:626-632. 10.1097/NEN.0b013e3181a491ce, 2728585, 19458547.
13. Gordillo G, Fang H, Park H, Roy S. Nox-4-dependent nuclear H2O2 drives DNA oxidation resulting in 8-OHdG as urinary biomarker and hemangioendothelioma formation. Antioxid Redox Signal 2010, 12:933-943. 10.1089/ars.2009.2917, 2935344, 19817625.
14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
15. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004, 22:1110-1117. 10.1200/JCO.2004.10.148, 15020613.
16. Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, Yoder MC, Semenza GL, Nicolls MR. Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest 2011, 121:2336-2349. 10.1172/JCI46192, 3104770, 21606594.
17. Oladipupo S, Hu S, Kovalski J, Yao J, Santeford A, Sohn RE, Shohet R, Maslov K, Wang LV, Arbeit JM. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci 2011, 108:13264-13269. 10.1073/pnas.1101321108, 3156154, 21784979.
18. Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008, 217:319-327. 10.1002/jcp.21503, 2716010, 18506785.
19. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997, 30:535-541. 10.1161/01.HYP.30.3.535, 9322978.
20. Chen TH, Wang JF, Chan P, Lee HM. Angiotensin II stimulates hypoxia-inducible factor 1α accumulation in glomerular mesangial cells. Ann N Y Acad Sci 2005, 1042:286-293. 10.1196/annals.1338.051, 15965074.
21. Sanchez-Lopez E, Lopez AF, Esteban V, Yague S, Egido J, Ruiz-Ortega M. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1α induction and redox mechanisms in the kidney. Antiox Redox Signal 2005, 7:1275-1284.
22. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 1995, 77:638-643. 10.1161/01.RES.77.3.638, 7641334.
23. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613. 231459, 8756616.
24. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996, 56:3436-3440.
25. Patel N, Kalra VK. Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells. J Biol Chem 2010, 285:20570-20579. 10.1074/jbc.M110.119495, 2898343, 20448047.